[Hemodialysis - a therapy for schizophrenia?].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H Hippius.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Three types of modern psychotropic drugs strongly influenced the practice of psychiatric therapy during the past 25 years: Minor tranquilizers, Antidepressants, and Neuroleptics. 1. From the clinical point of view the effects of tranquilizers are more unspecific as compared to those of neuroleptic and antidepressant drugs. Only with the latter two it is possible to treat manifestations of endogenous psychoses (schizophrenic and affective psychoses). The appraisal of both, the advantages (e.g. effectiveness on the symptomatology of acute psychotic manifestations or prophylactic effect in longtime application) and the risks (e.g. side-effects) have to be the basis of treatment of each single patient. 2. The recovery of biochemical mechanisms of neuroleptic and antidepressant drugs (especially of the effects on biogenic amines in CNS) is the most important advance in clearing up the biochemical disturbances in endogenous psychoses.
76 depressive patients (male and female) suffering from different kinds of depression (involutional, uni-and bipolar, neurotic, postpartum) showed no reduced serum iron levels. Even after a three to five weeks therapy with tricyclic antidepressants the serum iron levels of 17 of these patients were still within the normal range. On the basis of these results we can neither see a correlation between hyposideremia and the depressive syndrome, nor a hint for a decrease of serum iron levels under treatment with tricyclic antidepressants.
Three open studies with Lenperone were performed. 50 hospitalized schizophrenic patients were treated 20-30 days with Lenperone. The therapeutic effective dose was 30-50 mg/day. The highest daily dosage was 90 mg. Patients were examined on fixed observation days and the findings were documented by means of the AMP system. AMP data were analyzed at symptom and syndrome level and compared using an analysis of covariance. In the described dosage Lenperone acted only little sedating, strong antipsychotic and caused only a few single extrapyramidal and little autonomic side effects. The dosage is limited because of the effect on heart and blood circulation. Lenperone caused a good improvement of depressive symptoms in the schizophrenic patients. Lenperone was well tolerated and slowed a rapid onset of its antipsychotic effect. It caused a steady improvement of productive schizophrenic symptoms. For better knowledge of the profile of the effects of Lenperone, a trial in depressive paranoid syndromes, for example schizoaffective psychoses, would be interesting; a double-blind trial in comparison to a well-known antipsychotic would be very useful.
Explore the source record for details and available documents.
26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol. Psychopathological symptoms and parkinsonism were studied before and during the treatment. HVA and 5-HIAA concentrations in CSF were determined immediately before and after 5 or 15 days of treatment. After 5 days of treatment a slight effect was observed on psychotic symptoms and on the extrapyramidal motor system, as well as an elevation of HVA and 5-HIAA concentrations in CSF. After 15 days of treatment the extrapyramidal and antipsychotic effects were significant, but the rise of HVA was smaller than after 5 days of treatment; 5-HIAA remained unchanged. These different time courses of the neuroleptic effects on psychopathological symptoms, on extrapyramidal system and on monoamine metabolites concentration in CSF could be interpreted as a development of drug tolerance in relation to the biochemical parameters.
The time-course of psychopathological symptoms, of extrapyramidal side effects, and of changes in cerebrospinal fluid (CSF) concentration of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were simultaneously studied during Haloperidol treatment of 14 psychotic patients with chronic organic brain damage. After 15 days of treatment significant antipsychotic effect was found, while Parkinsonism scores in clinical and experimental tests increased only slightly. CSF concentration of HVA increased significantly by 150% compared to the baseline value (p less than 0.05) and 5-HIAA remained unchanged. No correlation was found between the clinical and biochemical variables studied. The comparison of these results with those obtained in patients without brain damage suggests that different psychopathological and extrapyramidal responses to neuroleptics are not strictly associated with specific HVA changes in CSF.
Palmomental reflex, glabellar reflex and oral responses were studied in the course of a treatment with Haloperidol in 14 psychotic patients with a chronic organic brain damage. An increase of the three responses was found; maximum intensity and frequency of the primitive reflexes were reached during the first 5 days of treatment. There was no correlation found between the intensity of primitive reflexes and changes of psychopathological symptoms, of extrapyramidal scores and of homovanillic acid (=HVA) and 5-hydroxyindoleacetic acid (5=5-HIAA) concentration in cerebrospinal fluid (=CSF). The presence of primitive responses is interpreted as a "decompensation phenomenon" induced by neuroleptics, probably in relation to an effect on the central nervous system (=CNS) dopamine receptors. It is suggested that the appearance of several definite, primitive reflexes during neuroleptic therapy may have some diagnostic and prognostic significance.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Symptoms of 1830 psychiatric patients from Berlin and of 783 patients from Zurich were assessed using the AMP-system. The symptoms were analysed according to their frequency and their potency to differentiate diagnostic groups. The following 4 categories of symptoms proved to be useful: frequently occurring and specific or unspecific, rarely occurring and specific or unspecific. Factor analyses of the frequently occurring unspecific symptoms yielded three general dimensions, i.e., "depression", "disturbance of memory and thinking" and "hostility".
Lofepramine, an imipramine derivative, shows lower acute toxicity in animals when compared with desipramine and imipramine. Its anticholinergic effect is less pronounced than that of desipramine. In an open clinical trial lofepramine showed a marked antidepressive action. A double-blind multicenter trial of lofepramine v. imipramine, evaluated by means of the AMP system, showed a remarkable degree of concurrence with regards to the effects of those two products.
The rating systems used in psychiatry consider sometimes different ways of classifying parameters, such as the valuability and the certainty of decision. Those two parameters have been analysed by means of the AMP-ratings of two samples (Berlin: 1879 patients, Zürich: 786 patients). We have found that the reply "not valuable" appears much less frequently than the reply "questionable valuable". For delusional symptoms and disorders of perception the certainty of decision is lowest. The various analyses carried out lead us to the conclusion that without loosing informatory value of any consequence we can renounce any separate documentation on valuability and certainty of decision.